2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Blood Banking, Clinical Procedures, Treatment Considerations, Combination Therapy, Drug Development, Drug-Drug Interactions, Supportive Care, Therapy Sequence, Biological Therapies, Transfusion, Vaccines, Non-Biological Therapies, Opioids, Women’s Health, Adverse Events, Biological Processes, Hematopoiesis, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Bleeding and Clotting, Thromboembolism, Thrombotic Disorders, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Immunology, Immunodeficiency, Infectious Diseases, Bacterial, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4715 Real-world prevalence and risk factors for venous thromboembolism in sickle cell disease: Hydroxyurea use and lower neutrophils associate with lower risk of VTE in the grndad registry

William Beau Mitchell, MD, Jessica Hiley2, Jane A Little, MD3, Payal Desai, MD4, Draw Julie Kanter, MD5, Sophie Lanzkron, MD, MHS6, Guolian Other Person Kang, PhD7, Deepa Manwani I, MD8
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 University of Arkansas for Medical Sciences College of Medicine, Little Rock, Arkansas, United States
3 UNC Chapel Hill, Chapel Hill, North Carolina, United States
4 Wake Forest University, Winston-Salem, North Carolina, United States
5 University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States
6 Thomas Jefferson University, Philadelphia, Pennsylvania, United States
7 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States

Background: Sickle Cell Disease (SCD) is characterized by chronic hemolysis, systemic inflammation, and endothelial dysfunction, all of which contribute to recurrent painful vaso-occlusive episodes and a hypercoagulable state, increasing the risk of venous thromboembolism (VTE).  Building upon prior cohort and large administrative database studies, we used the Globin Research Network for Data and Discovery (GRNDaD) registry, a real-world, curated, prospective database used by the National Alliance of Sickle Cell Centers with more than 70 clinical sites in the US, to further evaluate the burden of VTE and its associated risk factors among people living with SCD.

Methods: The primary outcomes of this study are the prevalence of VTE events and the relative risks associated with risk and protective factors. This is a cross-sectional study using the first study visit for each participant with VTE data available in GRNDaD. Baseline characteristics were compared between participants with and without VTE using the Wilcoxon rank-sum test for continuous variables and the chi-square test for categorical variables. Modified Poisson regression with robust variance was used to evaluate associations between risk factors and DVT outcomes and to estimate adjusted relative risks (aRR) and 95% confidence intervals (CI).

Results: In total, 2523 patients with genotypes HbSS, Sβ0, SC, and Sβ+  with an average age of 33 years were included in the analysis, with 371 (15%, 95% CI: 13%-16%) and 358 (14%, 95% CI: 13%-16%) having deep vein thrombosis (DVT) and pulmonary embolism (PE), respectively.  Female sex accounted for 57%, and the SS genotype accounted for 65% of the dataset. HU use was reported in 74%. Both DVT and PE prevalence increased with age; DVT rose from 2.2% in children younger than 10 years to 3.2%,  8.5%, 21%, and 43% in individuals aged 10-19, 20–29, 30–69, and ≥70 years, respectively. Corresponding PE rates were 1.7%, 4.2%, 12%, 20%, and 23%.

Compared to patients without DVT and PE, those with DVT and PE were of older age (DVT: median 38, interquartile/IQR 32-48 vs 30, 21-41, p < 0.0001; PE: 37, 29-47 vs 31, 21-42, p < 0.0001), more likely to be female (DVT: 238 (65%) vs 1162 (56%), p = 0.001; PE: 232 (66%) vs 1166 (56%), p < 0.0001),  less likely to be on HU (DVT: 154 (55%) vs 1111 (77%), p < 0.0001; PE: 143 (54%) vs 1121 (78%), p < 0.0001), had higher absolute neutrophil count (ANC) (DVT: median 5.2, 3.6-7.5 vs 4.7, 3.2-6.7, p <0.0001; PE: 5.2, 3.5-7.2 vs 4.7, 3.2-6.7, p = 0.0004), and lower HbF (DVT: median 4.2, 1.6-10.6 vs 6.2, 2.1-14.2, p < 0.0001; PE: 4.4, 1.6-9.7 vs 6.2 2.0-14.2, p < 0.0001). They were also more likely to have a history of acute chest syndrome (ACS) (DVT: 249 (69%) vs 962 (45%),  p < 0.0001; PE: 255 (73%) vs 954 (45%), p < 0.0001). In female patients, pregnancy was more common in those with VTE (DVT: 113 (50%) vs 359 (34%), p < 0.0001; PE: 108 (48%) vs 365 (34%), p < 0.0001).

Multivariable modified Poisson regression analyses, which included age, sex, genotype, ACS, and HU use, identified SS genotype (DVT: aRR=1.43, 95% CI: 1.07-1.92 vs. non-SS genotype), female sex (PE: aRR=1.33, 95% CI: 1.05-1.68), older age (DVT/PE: aRR=1.03, 95% CI: 1.02-1.03), and ACS (DVT: aRR=1.38, 95% CI: 1.05-1.82; PE: 2.20, 95% CI: 1.63-2.95), as independent risk factors. In contrast, HU had a strong protective effect (DVT: aRR=0.52, 95% CI: 0.42-0.65; PE: 0.55, 95% CI: 0.43-0.69). After adjusting for factors listed above, a higher ANC was associated with increased PE risk (PE: aRR=1.02, 95% CI: 1.004-1.04).

Conclusions: DVT and PE were nearly equally prevalent in this cohort. The overall prevalence of VTE in this data registry (15%) exceeds previously reported prevalence rates for people living with SCD, and is greater than 7-fold that of young adult patients without SCD (less than 2%). HU is widely used in this cohort and is associated with a lower rate of VTE. Higher ANC, but not white blood cell count, was associated with VTE, which could be linked to the protective effect of HU on neutrophil-driven thromboinflammation. Future analysis of this data set will provide longitudinal incidence rates for VTE and temporal analyses of risk factors. This study demonstrates the value of the real-world GRNDaD database for evaluating SCD-related outcomes and their risk and protective factors.

William Beau Mitchell, MD: No relevant conflicts of interest to declare.